Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
The global TCIM market is expected to reach nearly US$ 600 billion by 2025
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
The iStent platform uses tiny surgical implants to lower eye pressure by restoring the eye’s natural fluid drainage system in patients with glaucoma
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Approximately 35% of male cancer patients and 12% of female cancer patients at Paras Health were diagnosed with tobacco-related cancers
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
Phytonadione Injectable Emulsion possesses the same type and degree of activity as does naturally-occurring vitamin K
Subscribe To Our Newsletter & Stay Updated
